Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.

Antimicrobial agents and chemotherapy - 1 Aug 2004

Grohs Patrick, Podglajen Isabelle, Gutmann Laurent

Abstract excerpt

Three sets of mutants of Bacillus anthracis resistant to fluoroquinolones were selected on ciprofloxacin and moxifloxacin in a stepwise manner from a nalidixic acid-resistant but fluoroquinolone-susceptible plasmidless strain harboring a Ser85Leu GyrA mutation. A high level of resistance to fluoroquinolones could be obtained in four or five selection steps. In each case, ParC was the secondary target. However, in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aza Compounds
Share to Bacillus anthracis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ciprofloxacin

Share to DNA Gyrase

Share to DNA Topoisomerase IV

Share to DNA Topoisomerases, Type I

Share to Moxifloxacin

Share to Quinolines

Source

Open in PubMed Open full text

Identifiers

PMID: 15273116
DOI: 10.1128/AAC.48.8.3024-3027.2004
PMCID: PMC478509

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.PMID 15273116Read ↗

Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance.Semantic proximity Read ↗

Genomewide screening for novel genetic variations associated with ciprofloxacin resistance in Bacillus anthracis.Semantic proximity Read ↗

Primary targets of fluoroquinolones in Streptococcus pneumoniae.Semantic proximity Read ↗

parC mutations in fluoroquinolone-resistant Borrelia burgdorferi.Semantic proximity Read ↗

Topoisomerase IV mutations in quinolone-resistant salmonellae selected in vitro.Semantic proximity Read ↗

Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.Semantic proximity Read ↗

ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.Semantic proximity Read ↗

Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.Semantic proximity Read ↗

Fluoroquinolone-resistant mutants of Burkholderia cepacia.Semantic proximity Read ↗

In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.Semantic proximity Read ↗

DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.Semantic proximity Read ↗

Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.